DHFR and leukemia: Methotrexate is among others administered to children with leukemia in order to provide CNS prophylaxis and apparently this agent, which is the dihydrofolate reductase inhibitor, alters the distribution of intracellular folates, decreases the CSF folates and increases MAPT concentrations [29].